Triple Immunotherapy Combination Potential Treatment for Pancreatic Cancer
Researchers from Rutgers Cancer Institute, with RWJBarnabas Health and in collaboration with investigators from MD Anderson, discovered a novel triple immunotherapy combination, targeting checkpoints on both T cells and myeloid suppressor cells, that dramatically improved anti-tumor responses by reprogramming the tumor microenvironment in preclinical models of PDAC. Learn more
